A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Aulos Bioscience, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
Essen Biotech
Essen Biotech
Second Life Therapeutics
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Regeneron Pharmaceuticals
Novelwise Pharmaceutical Corporation
Transgene
BioInvent International AB
Revolution Medicines, Inc.
Vedanta Biosciences, Inc.
Eisai Inc.
Hadassah Medical Organization
Leiden University Medical Center
Immuneering Corporation
Anaveon AG
Incyte Corporation
Sensei Biotherapeutics, Inc.
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
BioAtla, Inc.
Biogen
Kymab Limited
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Immunophotonics, Inc.
OncoResponse, Inc.
CJ Bioscience, Inc.
Immodulon Therapeutics Ltd
GI Innovation, Inc.
Salubris Biotherapeutics Inc
Vector Vitale LLC
NextCure, Inc.
Peter MacCallum Cancer Centre, Australia
OncoResponse, Inc.
Nektar Therapeutics
Nektar Therapeutics
Philogen S.p.A.
Herlev Hospital
M.D. Anderson Cancer Center
Institut d'Investigació Biomèdica de Bellvitge
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)